Monograph Title | Section | Source Publication | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication Sort descending | Description |
---|---|---|---|---|---|---|---|---|
POWDERED ASHWAGANDHA ROOT EXTRACT | COMPOSITION/Content of Withanolides | USP40–NF35 | 6804 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Add Solution B: Acetonitrile, filtered and degassed |
OIL- AND WATER-SOLUBLE VITAMINS CAPSULES | STRENGTH | USP40–NF35 | 7290 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Vitamin A, Method 1/Sample solution: Change Sample solution to: Sample stock solution AND Line 23 of Sample solution: Change Dilute a volume of this solution to: Sample solution: Dilute a volume of the Sample stock… Read More |
NEOTAME | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | First Supplement to USP40–NF35 | 8485 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 2 of USP Neotame Related Compound A RS: Change N-[3,3-Dimethylbutyl)-L-α-aspartyl]-L-phenylalanine. to: N-[N-(3,3-Dimethylbutyl)-L-α-aspartyl]-L-phenylalanine. |
ONDANSETRON INJECTION | USP Reference standards <11> | USP40–NF35 | 5443 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 2 of USP Ondansetron Related Compound A RS: Change 3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one. to: 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one hydrochloride. |
ISOSORBIDE DINITRATE EXTENDED-RELEASE TABLETS | Assay | USP40–NF35 | 4710 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Change Buffer solution, Mobile phase, Internal standard solution, Standard preparation, and Chromatographic system—Prepare as directed in the Assay under Diluted Isosorbide Dinitrate. to: Buffer solution—Dissolve 15.4 g of ammonium… Read More |
MONOBASIC POTASSIUM PHOSPHATE | IMPURITIES/Arsenic, Method I <211> | USP40–NF35 | 7847 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1: Change 3 µg/g to: NMT 3 µg/g |
OIL- AND WATER-SOLUBLE VITAMINS TABLETS | STRENGTH | USP40–NF35 | 7318 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Vitamin A, Method 1/Sample solution: Change Sample solution to: Sample stock solution AND Line 16 of Sample solution: Change Dilute a 10-mL volume of this solution to: Sample solution: Dilute a 10-mL volume of the Sample… Read More |
POTASSIUM CITRATE EXTENDED-RELEASE TABLETS | OTHER COMPONENTS/Content of Potassium | Revision Bulletin (Official April 01, 2017) | Online | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Sample solution: Change Transfer 3.0 mL of the clear filtrate, reserved from the Assay, to a 100-mL volumetric flask. to: Sample stock solution: Dilute the clear filtrate, reserved from the Assay, with water to obtain a solution containing about 160… Read More |
ISOSORBIDE DINITRATE EXTENDED-RELEASE TABLETS | Dissolution <711>/Test 2 | USP40–NF35 | 4710 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1: Change Buffer solution and Mobile phase—Prepare as directed in the Assay under Diluted Isosorbide Dinitrate. to: Buffer solution and Mobile phase—Prepare as directed in the Assay. AND Line 1 of Chromatographic system:… Read More |
ONDANSETRON ORAL SOLUTION | USP Reference standards <11> | USP40–NF35 | 5444 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 2 of USP Ondansetron Related Compound A RS: Change 3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one. to: 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one hydrochloride. |
CANDESARTAN CILEXETIL TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP40–NF35 | 8730 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 2 of USP Candesartan Cilexetil Related Compound D RS: Change 1-{[(Cyclohexyloxycarbonyloxy)carbonyl]oxy}ethyl 3-{[2’-(2-ethyl-2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-2-oxo-2,3-dihydro-1H-benzimidazole-4-carboxylate. to: 1-{[(Cyclohexyloxy)carbonyl]oxy}ethyl 3-({2’-(2-… Read More |
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS CAPSULES | STRENGTH | USP40–NF35 | 7336 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Vitamin A, Method 1/Sample solution: Change Sample solution to: Sample stock solution AND Line 23 of Vitamin A, Method 1/Sample solution: Change Dilute a volume of this solution to: Sample solution: Dilute a volume of the… Read More |
MEBENDAZOLE | IMPURITIES/Organic Impurities/Table 2 | USP40–NF35 | 4968 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Change footnotes dEthyl 5-benzoyl-1-methylbenzimidazol-2-ylcarbamate. eMethyl 5-(4-toluoyl)-1-methylbenzimidazol-2-ylcarbamate. to: dEthyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate. eMethyl 5-(4-toluoyl)-1H-benzimidazol-2-… Read More |
ONDANSETRON TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP40–NF35 | 5445 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 2 of USP Ondansetron Related Compound A RS: Change 3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one. to: 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one hydrochloride. |
FLUVOXAMINE MALEATE | CHEMICAL INFORMATION | Second Supplement to USP40–NF35 | 8797 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 4:Change 5-Methoxy-4’-(trifluoromethyl)valerophenone (E)-O-(2-aminoethyl)oxime, maleate (1:1) to: (E)-5-Methoxy-4’-(trifluoromethyl)valerophenone O-(2-aminoethyl)oxime, maleate (1:1) |
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS TABLETS | STRENGTH | USP40–NF35 | 7375 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Vitamin A, Method 1/Sample solution: Change Sample solution to: Sample stock solution AND Line 16 of Sample solution: Change Dilute a 10-mL volume of this solution to: Sample solution: Dilute a 10-mL volume of the Sample… Read More |
REAGENTS | REAGENT SPECIFICATIONS/Bromelain/Activity Determination | USP40–NF35 | 2339 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Buffer solution: Change Add 150 mg of sodium chloride to: Add 150 g of sodium chloride |
MEMANTINE HYDROCHLORIDE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Analysis | USP40–NF35 | 5000 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | In the variable definition list: Change CS = concentration of USP Memantine Hydrochloride RS in the Standard solution (µg/mL) to: CS = concentration of USP Memantine Hydrochloride RS in the Standard stock solution (mg/mL) |
PERPHENAZINE | IMPURITIES/Organic Impurities/Chromatographic system | USP40–NF35 | 5649 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Column: Change 4.6-mm to: 4.0-mm |
FLUVOXAMINE MALEATE | IMPURITIES/Organic Impurities/Table 1 | Second Supplement to USP40–NF35 | 8797 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Footnote b:Change 5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone (E)-O-[2-[(2-succinyl)amino]ethyl]oxime. to: (E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone O-[2-[(2-succinyl)amino]ethyl]oxime. AND Footnotes c– g: Delete the space before… Read More |
SHELLAC | IMPURITIES/Limit of Chloride | USP40–NF35 | 7869 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Control solution: Change 0.1 M hydrochloric acid VS, to: 0.01 M hydrochloric acid VS, |
REAGENTS, INDICATORS AND SOLUTIONS | SOLUTIONS/Volumetric Solutions/1 N Sulfuric Acid VS | USP40–NF35 | 2434 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 3 of Standardization: Change dried at 150° to: dried at 105° |
MYCOPHENOLATE MOFETIL FOR INJECTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP40–NF35 | 5250 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 2 of USP Mycophenolate Mofetil Related Compound B RS: Change (RS)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3H-isobenzofuranyl-1-one. to: (RS)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3H… Read More |
PROPANTHELINE BROMIDE | IMPURITIES/Organic Impurities/Chromatographic system | USP40–NF35 | 5882 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Run time: Change NMT to: NLT |
EFAVIRENZ | SPECIFIC TESTS/Enantiomeric Purity | Second Supplement to USP40–NF35 | Online | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Mobile phase: Change Hexane and ethanol (97:3) to: Hexane and absolute alcohol (97:3) |
<210> MONOSACCHARIDE ANALYSIS | PROCEDURES/Procedure 3: Enzymatic Hydrolysis and Analysis by RP-HPLC of DMB-labeled Sialic Acids | First Supplement to USP40–NF35 | 8059 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 6 of Analysis: Change (1 M = 1nmol/mL). to: (1 µM = 1nmol/mL). |
CALCIPOTRIENE OINTMENT | IMPURITIES/Organic Impurities | USP40–NF35 | 3114 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Footnote a of Table 1: Change (5Z,7Z,22E,24R)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1α,3β,24-triol. to: (5Z,7Z,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1α,3β,24-triol. |
MYCOPHENOLATE MOFETIL FOR ORAL SUSPENSION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP40–NF35 | 5251 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 2 of USP Mycophenolate Mofetil Related Compound B RS: Change (RS)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3H-isobenzofuranyl-1-one. to: (RS)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3H… Read More |
ROCURONIUM BROMIDE | IMPURITIES/Limit of 2-Propanol/Analysis | USP40–NF35 | 6066 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of the variable definition list: Change rU = peak response of any impurity from the Sample solution rS = peak response of rocuronium bromide from the Dilute standard solution to: rU = peak… Read More |
POTASSIUM CITRATE EXTENDED-RELEASE TABLETS | ASSAY/Procedure | Revision Bulletin (Official April 01, 2017) | Online | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Chromatographic system/Column: Change 10-µm to: 5-µm AND In the variable definition list in Analysis: Change rU = citrate peak area from the Sample solution rS = citrate peak area from… Read More |
G49 | CHROMATOGRAPHIC COLUMNS/Packings | First Supplement to USP40–NF35 | 8127 | 28-Jul-2019 | 20-Apr-2019 | USP42–NF37 | First Supplement to USP41–NF36 | Add G49—Dimethylpolysiloxane with chiral building block containing D- or L-valine as chiral agent (for amino acids). |
ENALAPRIL MALEATE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Table 1 | USP40–NF35 | 3971 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Row 3 of Column 3: Change 100 to: 200 |
MYCOPHENOLATE SODIUM | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP40–NF35 | 5256 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 2 of USP Mycophenolate Mofetil Related Compound B RS: Change (RS)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3H-isobenzofuranyl-1-one. to: (RS)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3H… Read More |
OIL-SOLUBLE VITAMINS CAPSULES | STRENGTH | USP40–NF35 | 7248 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Vitamin A, Method 1/Sample solution: Change Sample solution to: Sample stock solution AND Line 23 of Sample solution: Change Dilute a volume of this solution to: Sample solution: Dilute a volume of the Sample stock… Read More |
ACETAMINOPHEN AND CODEINE PHOSPHATE CAPSULES | PERFORMANCE TESTS | First Supplement to USP40–NF35 | 8201 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Dissolution <711>/Analysis:Change Determine the labeled amount of acetaminophen to: Determine the percentage of the labeled amount of acetaminophen AND In the Calculate statement of Uniformity of Dosage Units <905>/Procedure for content… Read More |
ENOXAPARIN SODIUM INJECTION | SPECIFIC TESTS/Anti-Factor IIa Activity | USP40–NF35 | 3982 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Delete Standard solutions: Dilute USP Enoxaparin Sodium Solution for Bioassays RS with pH 7.4 buffer to obtain four dilutions having concentrations in the range between 0.015 and 0.075 IU of Anti-Factor IIa activity/mL. |
MYCOPHENOLATE SODIUM | IMPURITIES/Organic Impurities | USP40–NF35 | 5256 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Footnote a of Table 2: Change (RS)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3H-isobenzofuranyl-1-one. to: (RS)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3H-isobenzofuran-1-one. |
OIL-SOLUBLE VITAMINS TABLETS | STRENGTH | USP40–NF35 | 7258 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Vitamin A, Method 1/Sample solution: Change Sample solution to: Sample stock solution AND Line 16 of Sample solution: Change Dilute a 10-mL volume of this solution to: Sample solution: Dilute a 10-mL volume of the Sample… Read More |
ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS | PERFORMANCE TESTS | First Supplement to USP40–NF35 | 8202 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Dissolution <711>/Analysis:Change Determine the labeled amount of acetaminophen to: Determine the percentage of the labeled amount of acetaminophen AND In the second Calculate statement in Uniformity of Dosage Units <905>/Procedure for… Read More |
<581> VITAMIN D ASSAY | ASSAY/Chromatographic Methods/Procedure 8 | USP40–NF35 | 462 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Clean-up chromatographic system: Add Flow rate: 1.1 mL/min AND Analytical chromatographic system: Add Flow rate: 1.0 mL/min |
FENOLDOPAM MESYLATE | USP Reference standards <11> | USP40–NF35 | 4159 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 2 of USP Fenoldopam Related Compound A RS: Change 1-Methyl-3-benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-, methanesulfonate (salt). C17H18ClNO3 · CH4SO3 415.89 to: 6-Chloro-1-(4-hydroxyphenyl)-3-… Read More |
PEMETREXED DISODIUM | IMPURITIES/Organic Impurities/Table 2 | USP40–NF35 | 5588 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Footnote b: Change {4-[2-(2-Amino-1-methyl-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-4-L-glutamyl-L-glutamic acid. to: {4‐[2‐(2‐Amino‐4‐oxo‐4,7‐dihydro‐1H‐pyrrolo[2,3‐d]pyrimidin‐5‐yl)ethyl]benzoyl}‐4‐L‐glutamyl‐L‐glutamic acid. |
OIL-SOLUBLE VITAMINS WITH MINERALS CAPSULES | STRENGTH | USP40–NF35 | 7265 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Vitamin A/Sample solution: Change Sample solution to: Sample stock solution AND Line 21 of Sample solution: Change Further dilute this solution to: Sample solution: Dilute the Sample stock solution AND Line 2… Read More |
ERYTHROMYCIN OPHTHALMIC OINTMENT | ASSAY/Procedure/Analysis | First Supplement to USP40–NF35 | 8276 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 9 of the third variable definition list: Change P = potency of erythromycin C in USP Erythromycin B RS (mg/mg) to: P = potency of erythromycin C in USP Erythromycin C RS (mg/mg) |
DOXAZOSIN MESYLATE | ASSAY/Procedure/System suitability/Suitability requirements | USP40–NF35 | 3874 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Resolution: Change NLT 4 to: NLT 2 |
GADOTERIDOL | Chromatographic purity/Test 2 (Nongadolinium-Containing Impurities) | USP40–NF35 | 4360 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of pH 5.0 Buffer: Change 50 mM Ammonium to: 50 mM Ammonium phosphate buffer AND Line 1 of pH 7.0 Buffer: Change 50 mM Ammonium to: 50 mM Ammonium phosphate buffer |
PEMETREXED FOR INJECTION | ASSAY/Procedure/Analysis | USP40–NF35 | 5590 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | In the variable definition list: Change Mr2 = molecular weight of pemetrexed disodium, 597.49 to: Mr2 = molecular weight of pemetrexed disodium (anhydrous), 473.37 |
OIL-SOLUBLE VITAMINS WITH MINERALS TABLETS | STRENGTH | USP40–NF35 | 7280 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Vitamin A/Sample solution: Change Sample solution to: Sample stock solution AND Line 15 of Sample solution: Change Further dilute this solution to: Sample solution: Dilute the Sample stock solution AND Line 2… Read More |
LEVOTHYROXINE SODIUM TABLETS | IMPURITIES/Limit of Liothyronine Sodium | First Supplement to USP40–NF35 | 8328 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 4 of Analysis: Change Calculate the percentage of levothyroxine sodium (C15H11I3NNaO4) to: Calculate the percentage of liothyronine sodium (C15H11I3NNaO4) |
ONDANSETRON HYDROCHLORIDE | USP Reference standards <11> | USP40–NF35 | 5441 | 28-Jul-2017 | 1-Aug-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 2 of USP Ondansetron Related Compound A RS: Change 3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one. to: 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one hydrochloride. |